PE20090212A1 - Kit de vacuna para la inmunizacion primaria - Google Patents
Kit de vacuna para la inmunizacion primariaInfo
- Publication number
- PE20090212A1 PE20090212A1 PE2008000772A PE2008000772A PE20090212A1 PE 20090212 A1 PE20090212 A1 PE 20090212A1 PE 2008000772 A PE2008000772 A PE 2008000772A PE 2008000772 A PE2008000772 A PE 2008000772A PE 20090212 A1 PE20090212 A1 PE 20090212A1
- Authority
- PE
- Peru
- Prior art keywords
- crm
- conjugate
- conjugated
- optionally
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UN KIT DE VACUNA QUE COMPRENDE ALMENOS 9 CONJUGADOS DE SACARIDOS DE LOS CUALES 2 A 7 ESTAN CONJUGADOS CON CRM; DICHO KIT COMPRENDE: A)UN PRIMER ENVASE CONTENIENDO: a)UN CONJUGADO DE SACARIDO DE Hib (H. influenzae tipo b) EN PRESENCIA DE CRM (proteina transportadora), DT (toxoide de difteria) O SU DERIVADO; b)AL MENOS UN CONJUGADO DE SACARIDO CONJUGADO CON CRM; c)OPCIONALMENTE UN CONJUGADO DE SACARIDO NO CONJUGADO CON CRM, DT O SU DERIVADO; B)UN SEGUNDO ENVASE CONTENIENDO: a)AL MENOS UN CONJUGADO DE SACARIDO CONJUGADO CON CRM; b)AL MENOS UN CONJUGADO DE SACARIDOS NO CONJUGADO CON CRM, DT O SU DERIVADO; C)OPCIONALMENTE UN TERCER ENVASE QUE COMPRENDE: a)AL MENOS UN CONJUGADO DE SACARIDO CONJUGADO CON CRM; b)OPCIONALMENTE AL MENOS UN CONJUGADO DE SACARIDO NO CONJUGADO CON CRM, DT O SU DERIVADO. DONDE: LA CARGA TOTAL DE CRM ES INFERIOR A 35 ug; EL CONJUGADO DE SACARIDOS DE Hib ESTA PRESENTE EN DOSIS MENOR A 15ug; LA DOSIS MEDIA DE CRM POR CONJUGADO DE SACARIDOS CONJUGADOS CON CRM ES MENOR A 15ug; Y OPCIONALMENTE PUEDE CONTENER PT (toxoide de pertusis), PRN (pertactina), DTP (infanrix-hexa, pediacel), IPV (vacuna antipoliomelitica inactivada), TT (toxoide de tetano) Y FHA (antihemaglutinina filamentosa) Y OPCIONALMENTE SACARIDOS CAPSULARES DE Neisseria meningitidis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0708522A GB0708522D0 (en) | 2007-05-02 | 2007-05-02 | Vaccine |
GB0712658A GB0712658D0 (en) | 2007-06-28 | 2007-06-28 | Vaccine |
GB0802108A GB0802108D0 (en) | 2008-02-05 | 2008-02-05 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090212A1 true PE20090212A1 (es) | 2009-03-30 |
Family
ID=39714236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000772A PE20090212A1 (es) | 2007-05-02 | 2008-04-30 | Kit de vacuna para la inmunizacion primaria |
Country Status (21)
Country | Link |
---|---|
US (2) | US20100074918A1 (es) |
EP (2) | EP2142211A1 (es) |
JP (2) | JP2010525035A (es) |
KR (1) | KR20100017569A (es) |
CN (2) | CN101687028A (es) |
AR (1) | AR066376A1 (es) |
AU (1) | AU2008248640A1 (es) |
BR (1) | BRPI0810778A2 (es) |
CA (1) | CA2685506A1 (es) |
CL (1) | CL2008001258A1 (es) |
CO (1) | CO6241131A2 (es) |
CR (1) | CR11142A (es) |
DO (1) | DOP2009000252A (es) |
EA (2) | EA201490303A1 (es) |
IL (1) | IL201782A0 (es) |
MA (1) | MA31428B1 (es) |
MX (1) | MX2009011837A (es) |
PE (1) | PE20090212A1 (es) |
TW (1) | TW200914042A (es) |
UY (1) | UY31064A1 (es) |
WO (1) | WO2008135514A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA76952C2 (uk) * | 2000-06-29 | 2006-10-16 | Глаксосмітклайн Байолоджікалз С.А. | Полівалентна імуногенна композиція, спосіб її виготовлення, застосування у виробництві лікарського засобу для лікування або попередження захворювань, викликаних інфекцією haemophilus influenzae типу в та спосіб імунізації людини-хазяїна від захворювання, викликаного haemophilus influenzae типу в |
HUE045482T2 (hu) | 2005-06-27 | 2019-12-30 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
WO2013063292A1 (en) | 2011-10-25 | 2013-05-02 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
JP6440619B2 (ja) * | 2012-10-12 | 2018-12-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 混合ワクチン用の架橋されていない無細胞百日咳抗原 |
US20140193451A1 (en) * | 2012-10-17 | 2014-07-10 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
US9849066B2 (en) * | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
KR102225282B1 (ko) | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
EP3530285B1 (en) * | 2016-10-20 | 2023-08-09 | KM Biologics Co., Ltd. | METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT |
WO2023200704A1 (en) | 2022-04-11 | 2023-10-19 | Sanofi Pasteur Inc. | Protein-saccharide conjugation with sodium cyanoborohydride |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
GB8516442D0 (en) | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
ZA88488B (en) | 1987-01-30 | 1988-10-26 | Smith Kline Rit | Hepatitis b virus surface antigens and hybrid antigens containing them |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
EP0299108B1 (en) | 1987-07-17 | 1994-05-18 | Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH | DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses |
IT1223334B (it) | 1987-11-02 | 1990-09-19 | Sclavo Spa | Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
GB8914122D0 (en) | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
WO1991001146A1 (en) | 1989-07-14 | 1991-02-07 | Praxis Biologics, Inc. | Cytokine and hormone carriers for conjugate vaccines |
ES2109921T3 (es) | 1989-07-25 | 1998-02-01 | Smithkline Beecham Biolog | Nuevos antigenos y procedimientos para su preparacion. |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
CA2067003A1 (en) | 1991-04-29 | 1992-10-30 | Peter J. Kniskern | Hbsag escape mutant vaccine |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
DE69324487T2 (de) | 1992-05-06 | 1999-08-12 | The President and Fellows of Harvard College, Cambridge, Mass. | Rezeptorbindende region des diphtherietoxius |
ES2334181T3 (es) | 1992-05-23 | 2010-03-05 | Glaxosmithkline Biologicals S.A. | Vacunas combinadas que comprenden antigeno de superficie de la hepatitis b y otros antigenos. |
PT652758E (pt) | 1992-06-18 | 2000-04-28 | Harvard College | Vacinas de toxina da difteria |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
NZ274376A (en) | 1993-09-22 | 1997-11-24 | Jackson H M Found Military Med | Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
DE69535036T3 (de) | 1994-07-15 | 2011-07-07 | The University of Iowa Research Foundation, IA | Immunomodulatorische oligonukleotide |
NZ304715A (en) | 1995-03-22 | 1999-07-29 | Jackson H M Found Military Med | Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
ES2157447T5 (es) | 1995-06-23 | 2011-04-29 | Smithkline Beecham Biologicals S.A. | Una composición de vacuna que comprende un antígeno conjugado de polisacárido de haemofilus influenzae tipo b adsorbido en fosfato de aluminio. |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
AU771330B2 (en) | 1998-08-19 | 2004-03-18 | Baxter Healthcare Sa | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide |
US6582706B1 (en) | 1998-12-21 | 2003-06-24 | Medimmune, Inc. | Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
NZ553554A (en) | 2000-06-20 | 2008-11-28 | Id Biomedical Corp | Streptococcus antigens |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
UA76952C2 (uk) | 2000-06-29 | 2006-10-16 | Глаксосмітклайн Байолоджікалз С.А. | Полівалентна імуногенна композиція, спосіб її виготовлення, застосування у виробництві лікарського засобу для лікування або попередження захворювань, викликаних інфекцією haemophilus influenzae типу в та спосіб імунізації людини-хазяїна від захворювання, викликаного haemophilus influenzae типу в |
UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
EP1409013B1 (en) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
EP1456231A2 (en) | 2001-12-20 | 2004-09-15 | Shire Biochem Inc. | Streptococcus antigens |
PT2395073T (pt) | 2002-11-01 | 2017-11-24 | Glaxosmithkline Biologicals Sa | Processo de secagem |
AU2004219910B2 (en) | 2003-03-13 | 2010-06-17 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
EP2425856A1 (en) * | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP5135220B2 (ja) * | 2005-09-01 | 2013-02-06 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 血清群c髄膜炎菌を含む複数ワクチン接種 |
MY150719A (en) * | 2005-12-22 | 2014-02-28 | Glaxosmithkline Biolog Sa | Pneumococcal polysaccharide conjugate vaccine |
-
2008
- 2008-04-30 AU AU2008248640A patent/AU2008248640A1/en not_active Abandoned
- 2008-04-30 CA CA002685506A patent/CA2685506A1/en not_active Abandoned
- 2008-04-30 EP EP08749959A patent/EP2142211A1/en not_active Ceased
- 2008-04-30 EP EP20130187404 patent/EP2682127A1/en not_active Withdrawn
- 2008-04-30 JP JP2010504749A patent/JP2010525035A/ja active Pending
- 2008-04-30 US US12/598,306 patent/US20100074918A1/en not_active Abandoned
- 2008-04-30 EA EA201490303A patent/EA201490303A1/ru unknown
- 2008-04-30 WO PCT/EP2008/055383 patent/WO2008135514A1/en active Application Filing
- 2008-04-30 CL CL2008001258A patent/CL2008001258A1/es unknown
- 2008-04-30 CN CN200880023236A patent/CN101687028A/zh active Pending
- 2008-04-30 MX MX2009011837A patent/MX2009011837A/es unknown
- 2008-04-30 EA EA200901340A patent/EA200901340A1/ru unknown
- 2008-04-30 KR KR1020097025153A patent/KR20100017569A/ko not_active Application Discontinuation
- 2008-04-30 PE PE2008000772A patent/PE20090212A1/es not_active Application Discontinuation
- 2008-04-30 CN CN201410208570.XA patent/CN103933564A/zh active Pending
- 2008-04-30 UY UY31064A patent/UY31064A1/es unknown
- 2008-04-30 TW TW097115978A patent/TW200914042A/zh unknown
- 2008-04-30 BR BRPI0810778-5A patent/BRPI0810778A2/pt not_active IP Right Cessation
- 2008-04-30 AR ARP080101848A patent/AR066376A1/es unknown
-
2009
- 2009-10-27 IL IL201782A patent/IL201782A0/en unknown
- 2009-10-30 DO DO2009000252A patent/DOP2009000252A/es unknown
- 2009-11-27 CO CO09135810A patent/CO6241131A2/es not_active Application Discontinuation
- 2009-12-01 MA MA32397A patent/MA31428B1/fr unknown
- 2009-12-02 CR CR11142A patent/CR11142A/es not_active Application Discontinuation
-
2013
- 2013-05-17 US US13/896,375 patent/US20130251745A1/en not_active Abandoned
-
2014
- 2014-08-22 JP JP2014169195A patent/JP2015028032A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20130251745A1 (en) | 2013-09-26 |
WO2008135514A1 (en) | 2008-11-13 |
BRPI0810778A2 (pt) | 2011-09-13 |
MA31428B1 (fr) | 2010-06-01 |
AR066376A1 (es) | 2009-08-12 |
EP2142211A1 (en) | 2010-01-13 |
EA201490303A1 (ru) | 2014-05-30 |
CL2008001258A1 (es) | 2009-01-16 |
TW200914042A (en) | 2009-04-01 |
AU2008248640A1 (en) | 2008-11-13 |
JP2010525035A (ja) | 2010-07-22 |
DOP2009000252A (es) | 2010-01-31 |
CR11142A (es) | 2010-04-15 |
IL201782A0 (en) | 2010-06-16 |
KR20100017569A (ko) | 2010-02-16 |
MX2009011837A (es) | 2010-04-22 |
JP2015028032A (ja) | 2015-02-12 |
CN103933564A (zh) | 2014-07-23 |
CN101687028A (zh) | 2010-03-31 |
UY31064A1 (es) | 2009-01-05 |
CA2685506A1 (en) | 2008-11-13 |
EP2682127A1 (en) | 2014-01-08 |
CO6241131A2 (es) | 2011-01-20 |
US20100074918A1 (en) | 2010-03-25 |
EA200901340A1 (ru) | 2010-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090212A1 (es) | Kit de vacuna para la inmunizacion primaria | |
ES2681698T3 (es) | Vacunas de combinación con menores dosis de antígeno y/o adyuvante | |
BRPI0508813B8 (pt) | vacinas líquidas de combinação com baixa dose de conjugado de hib | |
CY1118732T1 (el) | Εμβολια κυστιδιων βασει gna1870 για προστασια ευρεως φασματος εναντι νοσων προκαλουμενων απο neisseria meningitidis | |
BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
CY1118492T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου norovirus | |
CY1111814T1 (el) | Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων | |
AR056397A1 (es) | Composicion inmunogenica | |
CY1110140T1 (el) | Εμβολιασμος με μηνιγγοκοκκικο συζευγμα | |
MA29714B1 (fr) | Vaccin | |
RU2006114677A (ru) | Жидкие вакцины для множественных серогрупп менингококков | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
PE20100366A1 (es) | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion | |
CO6160334A2 (es) | Metodo para la elaboracion de una vacuna de conbinacion para proteger contra polio | |
ATE539012T1 (de) | Standverpackung | |
DK1235589T3 (da) | Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen | |
MX348734B (es) | Vacunacion multiple que incluye meningococcus del serogrupo c. | |
UY26801A1 (es) | Composición de vacuna | |
PL2004225T3 (pl) | Schematy immunizacji koniugatami meningokokowymi | |
CY1113020T1 (el) | Εμβολια συνδυασμου για neisseria meningitidis | |
PE20080748A1 (es) | Vacuna a base de los de cepas de neisseria | |
DE60142615D1 (de) | Epitop-synchronisierung in antigen präsentierenden zellen | |
AR092896A1 (es) | Composiciones inmunogenicas | |
WO2007116409A3 (en) | Improved vaccines comprising multimeric hsp60 peptide carriers | |
BRPI0411875A (pt) | método de imunização contra os sorogrupos a e c de neisseria meningitidis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |